Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention

References

• CampbellJEJanickiJSWeberKTTemporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosteroneJ Mol Cell Cardiol1995271545608523418
   PubMedGoogle Scholar
• ChoudhuryAVarugheseGLipGYHTargeting the renin angiotensin aldosterone system in atrial fibrillation: a shift from electrical to structural therapy?Exp Opin Pharmacother200562193207
   PubMed Web of Science ®Google Scholar
• CruickshankJMLewisJMooreVReversibility of left ventricular hypertrophy by different types of antihypertensive therapyJ Hum Hypertens1992685901534582
   PubMed Web of Science ®Google Scholar
• CuspidiCAmbrosioniEManciaGRole of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational SurveyJ Hypertens20022013071412131527
   PubMed Web of Science ®Google Scholar
• CuspidiCMeaniSFusiVMetabolic syndrome and target organ damage in untreated essential hypertensivesJ Hypertens2004221991815361772
   PubMed Web of Science ®Google Scholar
• CuspidiCMuiesanMLValagussaLComparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) studyJ Hypertens200220229330012409969
   PubMed Web of Science ®Google Scholar
• DahlofBPennertKHanssonLReversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studiesAm J Hypertens19925951001532319
   PubMed Web of Science ®Google Scholar
• DahlofBLeft ventricular hypertrophy and angiotensin II antagonistsAm J Hypertens2001141748211243310
   PubMed Web of Science ®Google Scholar
• DahlofBZanchettiADiezJEffect of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophyJ Hypertens20022018556412195129
   PubMed Web of Science ®Google Scholar
• DevereuxRBWachtellKGerdtsEPrognostic significance of left ventricular mass changes during treatment of hypertensionJAMA20042922350615547162
   PubMed Web of Science ®Google Scholar
• DevereuxRBDahlofBGerdtsERegression of hypertensive left ventricular hypertrophy by losartan compared to atenololCirculation200411014566215326072
   PubMed Web of Science ®Google Scholar
• DisertoriMLatiniRMaggioniAPRationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrenceJ Cardiovasc Med200672938
   Google Scholar
• DucharmeASwedbergKPfefferMAPrevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAm Heart J20061519859116644318
   PubMedGoogle Scholar
• FogariRMugelliniADestroMLosartan and prevention of atrial recurrence in hypertensive patientsJ Cardiovasc Pharmacol200647465016424784
   PubMed Web of Science ®Google Scholar
• HealeyJSBaranchuckACrystalEPrevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A meta-analysisJ Am Coll Cardiol20054518323915936615
   PubMed Web of Science ®Google Scholar
• HennersdorfMGStrauerBEArterial hypertension and cardiac arrhythmiasJ Hypertens2001191677711212958
   PubMed Web of Science ®Google Scholar
• KaschinaEUngerTAngiotensin AT1/AT2 receptors: regulation, signalling and functionBlood Press200312708812797627
   PubMed Web of Science ®Google Scholar
• KannelWBWolfPABenjaminEJPrevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimatesAm J Cardiol1998822N9N
   PubMed Web of Science ®Google Scholar
• KlingbeilAUSchneiderMMartusPA meta-analysis of the effects of treatment on left ventricular mass in essential hypertensionAm J Med200311541612867233
   PubMed Web of Science ®Google Scholar
• KorenMJDevereuxRBCasalePNRelation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertensionAnn Intern Med1991114345521825164
   PubMed Web of Science ®Google Scholar
• LeonettiGCuspidiCHeart and vascular changes in hypertensionJ Hypertens199513Suppl 2S29S34
   Google Scholar
• LevyGAndersonKMSavageDDPrognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart StudyN Engl J Med1990322156162139921
   PubMed Web of Science ®Google Scholar
• MadridAHBuenoMGRebolloJMGUse of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillationCirculation2002106331612119249
   PubMed Web of Science ®Google Scholar
• MitchellGFVasanRSKeyesMJPulse pressure and risk of new onset atrial fibrillationJAMA20072977091517312290
   PubMed Web of Science ®Google Scholar
• MaggioniAPLatiniRCarsonPEValsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Am Heart J20051495485715864246
   PubMed Web of Science ®Google Scholar
• MalmqvistKKahanTEdnerMRegression of left ventricular hypertrophy in human hypertension with irbesartanJ Hypertens20001911677611403367
   PubMed Web of Science ®Google Scholar
• ManciaGZanchettiAAgabiti-RoseiEAmbulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophyCirculation1997951464709118514
   PubMed Web of Science ®Google Scholar
• OkinPMWacthellKDevereuxRBRegression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertensionJAMA20062961242816968848
   PubMed Web of Science ®Google Scholar
• PerliniSMuiesanMLCuspidiCMidwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometryCirculation20011036788311156879
   PubMed Web of Science ®Google Scholar
• ReudelhuberTLBernsteinKEDelafontainePIs angiotensin II a direct mediator of left ventricular hypertrophy? Time for another lookHypertension200749119620117452509
   PubMedGoogle Scholar
• RoggHde GasparoMGraedelEAngiotensin II-receptor sybtypes in human atria and evidence for alterations in patients with cardiac dysfunctionEur Heart J19961711121208809530
   PubMed Web of Science ®Google Scholar
• SchlaichMPSchobelHLangenfeldMRVInadequate suppression of angiotensin II modulates left ventricular structure in humansClin Nephrol19984915399543596
   PubMed Web of Science ®Google Scholar
• SchmiederREThe role on non-haemodynamic factors in the genesis of LVHNephron Dial Transplant200520261012
   PubMed Web of Science ®Google Scholar
• SchmiederRELangefeldMRFriedrichAAngiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertensionCirculation199694130498822984
   PubMed Web of Science ®Google Scholar
• SchmiederREMesserliFHGaravagliaGEDoes the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?Am J Med198884Suppl A136392975463
   PubMedGoogle Scholar
• SchmiederREMartusPKlingbeilAUReversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studiesJAMA19962751507138622227
   PubMed Web of Science ®Google Scholar
• SchmiederRESchlaichMFKlingbeilAUUpdate on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1998)Nephrol Dial Transplant19981356499550628
   PubMed Web of Science ®Google Scholar
• SchmiederRKjeldsenSEJuliusSReduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialJ Hypertens200624SupplS3 abstract
   PubMedGoogle Scholar
• SchneiderMPKlingbeilAUDellesCEffect of irbesartan versus atenolol on left ventricular mass and voltage. Results of the CardioVascular Irbesartan ProjectHypertension20044461615184349
   PubMed Web of Science ®Google Scholar
• SegaRTrocinoGLanzarottiAAlterations of cardiac structure in patients with isolated, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA]) StudyCirculation200110413859211560854
   PubMed Web of Science ®Google Scholar
• TrimarcoBDe LucaNRicciardelliBCardiac function in systemic hypertension before and after reversal of left ventricular hypertrophyAm J Cardiol198862745502971309
   PubMed Web of Science ®Google Scholar
• TsaiCTLaiLPLinJLRenin-angiotensin system gene polymorphisms and atrial fibrillationCirculation2004104260814
   Google Scholar
• VerdecchiaPPorcellatiCReboldiGLeft ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertensionCirculation200110420394411673343
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFBorgioniCChanges in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysisAm J Hypertens200316895914573325
   PubMed Web of Science ®Google Scholar
• VerdecchiaPReboldiGGattobigioRAtrial fibrillation in hypertension : predictors and outcomeHypertension2003412182312574085
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenololJ Am Coll Cardiol2005457121915734615
   PubMed Web of Science ®Google Scholar
• YasunariKMaedaKWatanabeTComparative effects of valsartan versus amlodipine on left ventricular and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophyJ Am Coll Cardiol20044321162315172423
   PubMed Web of Science ®Google Scholar